Price predictions, page-19

Based on the hard evidence of total number of sales of Ecclock in Japan, BOT estimate they could easily make $100m in the US market.
If $100m came to fruition, BOT should be over $1 ($100m divided by 1.3b shares x a PE of 15).
Clearly the SP at present indicates the market doesn't think this is going to happen anytime soon.

Qbrexza made $25m in sales last year. So if BOT, which has a product that is more effective than Qbrexza, only sells the same amount, then $25m divided by 1.3b shares x a PE of 15 times = $0.28

Of course, nothing in that price takes into account anti-microbial (which has fast track approval and regulatory protection for 5 years), acne (demonstrated exceptionally positive in Australia but flopped in the US - so needs a further trial to demonstrate how good it really is) and rosacea which had an encouraging Ph2 trial (the stuff works).

My thoughts are that in this current uncertain market of high inflation and interest rates, the market is being way shy, so I don't think now we can expect much more than a price in the 20c range after FDA approval. But an improved global financial environment may improve that.
I suspect in a year or two's time, when BOT has progressed at least anti-microbial, then we will hit the $1 mark. If we get as far (i.e. not taken out) as the whole quaddie (SB, acne, am and rosacea) completing Phase 3 trials, then we are in the $5 plus range.

But I could be completely and utterly wrong!